JP2015134763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015134763A5 JP2015134763A5 JP2015012350A JP2015012350A JP2015134763A5 JP 2015134763 A5 JP2015134763 A5 JP 2015134763A5 JP 2015012350 A JP2015012350 A JP 2015012350A JP 2015012350 A JP2015012350 A JP 2015012350A JP 2015134763 A5 JP2015134763 A5 JP 2015134763A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid pharmaceutical
- buffer
- glibenclamide
- pharmaceutically inert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000007787 solid Substances 0.000 claims 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 9
- 229960004580 glibenclamide Drugs 0.000 claims 9
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000000843 powder Substances 0.000 claims 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
- 229910052783 alkali metal Inorganic materials 0.000 claims 3
- 150000001340 alkali metals Chemical class 0.000 claims 3
- 239000002585 base Substances 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 235000002639 sodium chloride Nutrition 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000006171 Britton–Robinson buffer Substances 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99224107P | 2007-12-04 | 2007-12-04 | |
| US60/992,241 | 2007-12-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537028A Division JP5812318B2 (ja) | 2007-12-04 | 2008-12-03 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017009474A Division JP6377189B2 (ja) | 2007-12-04 | 2017-01-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015134763A JP2015134763A (ja) | 2015-07-27 |
| JP2015134763A5 true JP2015134763A5 (enExample) | 2015-11-19 |
| JP6084639B2 JP6084639B2 (ja) | 2017-02-22 |
Family
ID=40718143
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537028A Active JP5812318B2 (ja) | 2007-12-04 | 2008-12-03 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2015012350A Active JP6084639B2 (ja) | 2007-12-04 | 2015-01-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2017009474A Active JP6377189B2 (ja) | 2007-12-04 | 2017-01-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2018137703A Active JP6603762B2 (ja) | 2007-12-04 | 2018-07-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2019153477A Active JP6866438B2 (ja) | 2007-12-04 | 2019-08-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537028A Active JP5812318B2 (ja) | 2007-12-04 | 2008-12-03 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017009474A Active JP6377189B2 (ja) | 2007-12-04 | 2017-01-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2018137703A Active JP6603762B2 (ja) | 2007-12-04 | 2018-07-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2019153477A Active JP6866438B2 (ja) | 2007-12-04 | 2019-08-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8277845B2 (enExample) |
| EP (2) | EP2868315B1 (enExample) |
| JP (5) | JP5812318B2 (enExample) |
| CN (1) | CN101932308B (enExample) |
| CA (3) | CA3240562A1 (enExample) |
| CY (1) | CY1119256T1 (enExample) |
| DK (1) | DK2868315T3 (enExample) |
| ES (1) | ES2638977T3 (enExample) |
| HR (1) | HRP20171223T1 (enExample) |
| LT (1) | LT2868315T (enExample) |
| PL (1) | PL2868315T3 (enExample) |
| PT (1) | PT2868315T (enExample) |
| SI (1) | SI2868315T1 (enExample) |
| WO (1) | WO2009073711A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2868315T3 (pl) * | 2007-12-04 | 2018-06-29 | Biogen Chesapeake Llc | Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| WO2013086292A1 (en) * | 2011-12-09 | 2013-06-13 | Enject, Inc. | Glucagon formulations |
| CA2872012C (en) | 2012-05-08 | 2017-06-20 | Aeromics, Llc | New methods |
| MY189533A (en) * | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| CN106163506A (zh) | 2013-11-06 | 2016-11-23 | 埃罗米克斯公司 | 新配方 |
| WO2015134906A1 (en) * | 2014-03-07 | 2015-09-11 | Endologix, Inc. | Forming hydrogels and materials therefor |
| TW201613888A (en) * | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
| CN108348567B (zh) | 2015-05-29 | 2022-03-01 | 马里兰州立大学巴尔的摩分校 | 减少或预防由内皮细胞的机械刺激所致的内膜损伤的方法 |
| MA45574A (fr) | 2015-10-07 | 2019-05-15 | Biogen Chesapeake Llc | Procédés de traitement de lésions ou de pathologies liées à un dème du snc |
| US20170320862A1 (en) * | 2016-05-03 | 2017-11-09 | Cadila Healthcare Limited | Process for the preparation of brexpiprazole and intermediates thereof |
| KR102646250B1 (ko) | 2016-07-29 | 2024-03-11 | 레메디 파마슈티칼즈, 인크. | Sur1-trpm4 통로 저해제를 이용하는 의학적 치료 방법 |
| CN108210501B (zh) | 2016-12-14 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磺酰脲类药物的注射用药物组合物及其制备方法 |
| SG11201912673UA (en) | 2017-06-30 | 2020-01-30 | Murata Machinery Ltd | Conveying system and conveying method |
| CN108553428A (zh) * | 2018-05-29 | 2018-09-21 | 昆药集团股份有限公司 | 格列本脲制剂及其制备方法 |
| CN117320727A (zh) * | 2021-03-04 | 2023-12-29 | 生物切萨皮克有限责任公司 | 低吸附格列本脲制剂及方法 |
| US11541106B2 (en) | 2021-03-19 | 2023-01-03 | Eligo Bioscience | Method for killing bacteria with an engineered postbiotic |
| CN113274361B (zh) * | 2021-06-08 | 2022-05-06 | 吉林津升制药有限公司 | 一种烟酰胺冻干粉针剂及其制备方法 |
| JP2025506895A (ja) * | 2022-03-03 | 2025-03-13 | レメディー ファーマシューティカルズ， インコーポレイテッド | 低吸着性グリブリドキット、製剤および方法 |
| US12251389B1 (en) | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| US12251388B1 (en) | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4384975A (en) | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
| DE3833439A1 (de) | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
| US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
| GB9003185D0 (en) * | 1990-02-13 | 1990-04-11 | Ici Plc | Pharmaceutical compositions |
| CA2127877A1 (en) | 1992-01-21 | 1993-07-22 | Robert M. Platz | Improved process for preparing micronized polypeptide drugs |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| HUT75780A (en) | 1994-04-25 | 1997-05-28 | Kyowa Hakko Kogyo Kk | Method for stabilizing compound dx-52-1 (isoquinolino-pyrolo-pyrazine derivatives) and lyophilized composition thereof |
| US5747002A (en) | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
| US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
| JP4878664B2 (ja) * | 1996-12-24 | 2012-02-15 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定な液体インターフェロン処方物 |
| US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| NZ502569A (en) | 1997-07-29 | 2002-05-31 | Upjohn Co | Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4 |
| US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| JP2002516874A (ja) * | 1998-05-29 | 2002-06-11 | バイオジェン インコーポレイテッド | 組換えヒトインターフェロンβ−１Ａ（ＩＦＮ−β−１Ａ）処方物 |
| JP3956654B2 (ja) | 2000-06-29 | 2007-08-08 | 小野薬品工業株式会社 | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 |
| US6552082B2 (en) | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
| US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| AU2002306461A1 (en) | 2001-03-28 | 2002-10-15 | Rheologics, Inc. | In vivo delivery methods and compositions |
| US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| EP1399426A2 (en) | 2001-06-12 | 2004-03-24 | Active Pass Pharmaceuticals, Inc. | Compounds, compositions and methods for modulating beta-amyloid production |
| NZ531155A (en) * | 2001-07-17 | 2005-07-29 | N Gene Res Lab Inc | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| US7872048B2 (en) | 2004-09-18 | 2011-01-18 | University Of Maryland, Baltimore | Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel |
| JP4485806B2 (ja) | 2002-03-20 | 2010-06-23 | ユニヴァーシティ オブ メリーランド，ボルチモア | 神経系細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法 |
| DE10325989A1 (de) | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| DE10341414A1 (de) | 2003-09-05 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe |
| CA2566873C (en) | 2004-05-20 | 2013-02-12 | Diamedica Inc. | Use of drug combinations for treating insulin resistance |
| CA2642429A1 (en) | 2005-02-17 | 2006-08-24 | Instituto Del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
| US7659281B2 (en) | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
| EP2071917B1 (en) | 2006-09-29 | 2012-11-21 | Infa S.A. | Packaging system for pharmaceutical compositions and kit for intravenous administration |
| PL2868315T3 (pl) | 2007-12-04 | 2018-06-29 | Biogen Chesapeake Llc | Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty |
-
2008
- 2008-12-03 PL PL14188334T patent/PL2868315T3/pl unknown
- 2008-12-03 EP EP14188334.8A patent/EP2868315B1/en active Active
- 2008-12-03 CA CA3240562A patent/CA3240562A1/en active Pending
- 2008-12-03 CA CA2707484A patent/CA2707484C/en active Active
- 2008-12-03 LT LTEP14188334.8T patent/LT2868315T/lt unknown
- 2008-12-03 WO PCT/US2008/085384 patent/WO2009073711A1/en not_active Ceased
- 2008-12-03 US US12/746,164 patent/US8277845B2/en active Active
- 2008-12-03 CA CA3123813A patent/CA3123813C/en active Active
- 2008-12-03 EP EP08857974.3A patent/EP2224913B1/en active Active
- 2008-12-03 CN CN200880126038.6A patent/CN101932308B/zh active Active
- 2008-12-03 PT PT141883348T patent/PT2868315T/pt unknown
- 2008-12-03 JP JP2010537028A patent/JP5812318B2/ja active Active
- 2008-12-03 DK DK14188334.8T patent/DK2868315T3/en active
- 2008-12-03 ES ES14188334.8T patent/ES2638977T3/es active Active
- 2008-12-03 SI SI200831850T patent/SI2868315T1/sl unknown
-
2012
- 2012-09-11 US US13/610,335 patent/US8858997B2/en active Active
-
2014
- 2014-10-07 US US14/508,488 patent/US10117834B2/en active Active
-
2015
- 2015-01-26 JP JP2015012350A patent/JP6084639B2/ja active Active
-
2017
- 2017-01-23 JP JP2017009474A patent/JP6377189B2/ja active Active
- 2017-08-09 HR HRP20171223TT patent/HRP20171223T1/hr unknown
- 2017-08-29 CY CY20171100905T patent/CY1119256T1/el unknown
-
2018
- 2018-07-23 JP JP2018137703A patent/JP6603762B2/ja active Active
- 2018-09-21 US US16/138,173 patent/US10426729B2/en active Active
-
2019
- 2019-08-26 JP JP2019153477A patent/JP6866438B2/ja active Active
- 2019-09-27 US US16/585,255 patent/US10869835B2/en active Active
-
2020
- 2020-12-18 US US17/126,993 patent/US20210244669A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015134763A5 (enExample) | ||
| JP2017128569A5 (enExample) | ||
| JP2011505424A5 (enExample) | ||
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| HRP20210743T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| JP2015525763A5 (enExample) | ||
| JP2014139229A5 (enExample) | ||
| EA201400679A1 (ru) | Композиция сухого порошка производного азола для ингаляции | |
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| WO2013164789A3 (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
| JP2014511847A5 (enExample) | ||
| JP2016503058A5 (enExample) | ||
| FI3769781T3 (fi) | Stabiili anti-ifnar1-formulaatio | |
| HRP20240197T1 (hr) | Farmaceutski pripravak koji sadrži protuvirusni derivat dihidrokinazolina koji ima konfiguraciju s na položaju 4 | |
| RU2013148119A (ru) | Лиофилизированный препарат ботулотоксина | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| JP2013524782A5 (enExample) | ||
| WO2011066291A4 (en) | Lyophilization methods, compositions, and kits | |
| HK1247829A1 (zh) | 用於治疗HCV的β-D-2'-脱氧-2'Α-氟-2'-β-C-取代-2-改性N6-取代的嘌呤核苷酸 | |
| NZ602441A (en) | A fast dissolving pharmaceutical composition | |
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2017516848A5 (enExample) | ||
| JP2016513625A5 (enExample) |